Second Meeting of the JGL Scientific Advisory Board

JGL’s Scientific Advisory Board, an independent body comprised of top foreign and domestic experts who raise the science profile of the company’s projects, held its second annual meeting. The goal was to create a network of relevant, science-based knowledge that increases the company’s intellectual capital and brings innovative solutions for patients through interdisciplinary discussions and joint reflection.

“We welcome every new meeting of the Scientific Advisory Board and the opportunity to present our respective areas of expertise in person through lectures and discussions with members of the Advisory Board. It is a fantastic opportunity for independent experts to evaluate everything we do and for us to consider new opportunities for growth in our three strategic areas – flu and cold, ophthalmology and dermatology. The power of integration, which is scientifically sound and based on validated clinical needs of patients, is a prerequisite for the company’s growth and increased competitiveness,” says Mislav Vučić, CEO of JGL.

In cooperation with JGL’s experts, the Scientific Advisory Board conducted a series of innovative formulation, preclinical, clinical, and analytical studies in the past year, all with the aim of creating a network of relevant knowledge and identifying new projects for the company’s production and technology portfolio.

“I am proud to be a member of the JGL Scientific Advisory Board. I get to work with a team from an innovative pharmaceutical company and share new ideas with my peers from the Advisory Board. Since my research is focused on topical drug development, I am usually very active in discussions and have the opportunity to lead innovative studies with the JGL team, who approach each project with great enthusiasm. It is a great pleasure to work with such a level of respect, knowledge, expertise and excitement,” says Prof. Özgen Özer, PhD, member of the Advisory Board and Head of the Department of Pharmaceutical Technology at the Faculty of Pharmacy of Ege University in Izmir.

Another expert that joined the Advisory Board this year is Prof. Ralph Mösges, PhD, from the University of Cologne, who is a world-renowned expert in allergology, pulmonology and clinical immunology. Prof. Mösges has actively participated in working groups of regulatory agencies (EMA, FDA, BfArM) and conducted a number of methodological and clinical research studies in areas of his scientific interest. He has participated in over 180 clinical trials and is a board member of the International Standardization Committee for the Objective Assessment of the Upper Airways (ISCOANA) and the working group of the International Rhinologic Society (IRS), the guideline committee of the German Academy of Otorhinolaryngology, Head and Neck Surgery and its working groups for developing guidelines on rhinosinusitis and sudden deafness.

The Advisory Board consists of nine experts, internationally recognised in their respective fields. In addition to those already mentioned, members include Prof. Henning H. Blume, PhD, Prof. Stipan Jonjić, PhD, Jag Ahluwalia, PhD, Prof. Vladimir Trkulja, PhD, Chief Physician Sonja Jandroković, MD, PhD, Andreas Bilstein, PhD, and Prof. Jasmina Lovrić, PhD. The team is coordinated by Zdravka Knežević, PhD, Director of Scientific Operations at JGL, who says that expectations for this year’s meeting are high because they had already raised the bar last year and have since then pushed the company forward towards developing complex projects and its own records.

To make this website run properly and to improve your experience, we use cookies. For more detailed information, please check our Privacy and personal data protection.

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.